About Nimbus Therapeutics
Nimbus Therapeutics is a company based in Cambridge (United States) founded in 2009. Nimbus Therapeutics has raised $685 million across 12 funding rounds from investors including Pfizer, Schrödinger and Citadel. The company has 81 employees as of December 31, 2022. Nimbus Therapeutics offers products and services including TYK2 inhibitor, HPK1 inhibitor, and ACC inhibitor. Nimbus Therapeutics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Aclaris Therapeutics, among others.
- Headquarter Cambridge, United States
- Employees 81 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nimbus Discovery Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$685 M (USD)
in 12 rounds
-
Latest Funding Round
$210 M (USD), Series F
Sep 06, 2023
-
Investors
Pfizer
& 20 more
-
Employee Count
81
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Nimbus Therapeutics
Nimbus Therapeutics offers a comprehensive portfolio of products and services, including TYK2 inhibitor, HPK1 inhibitor, and ACC inhibitor.
Inhibitor for immune-mediated diseases through clinical development.
Inhibitor for oncology applications in drug discovery.
Inhibitor targeting liver diseases via partnerships.
People of Nimbus Therapeutics
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Nimbus Therapeutics
Nimbus Therapeutics has successfully raised a total of $685M across 12 strategic funding rounds. The most recent funding activity was a Series F round of $210 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Nimbus Therapeutics
Nimbus Therapeutics has secured backing from 21 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Pfizer, Schrödinger and Citadel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A biotechnology venture capital firm investing in innovative science.
|
Locked | Locked | Locked | |
|
Corporate backed venture capital fund investing in multiple sectors
|
Locked | Locked | Locked | |
|
Venture capital firm investing in life science and biotechnology sectors
|
Locked | Locked | Locked |
Investor details for Nimbus Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nimbus Therapeutics
Investment portfolio details for Nimbus Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Nimbus Therapeutics
Detailed financials for Nimbus Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nimbus Therapeutics Comparisons
Peer comparison for Nimbus Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Nimbus Therapeutics
Nimbus Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Aclaris Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
Detailed competitors of Nimbus Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nimbus Therapeutics
Complete news archive for Nimbus Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nimbus Therapeutics
Nimbus Therapeutics was founded in 2009 and raised its 1st funding round 1 year after it was founded.
Nimbus Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Jeb Keiper is the current CEO of Nimbus Therapeutics.
Nimbus Therapeutics is a funded company, having raised a total of $685M across 12 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Nimbus Therapeutics is 81.
Nimbus Therapeutics was founded in 2009 in Cambridge, United States, within the biotechnology sector. Targeted therapeutics are developed by the company for cancer, metabolic, and inflammatory diseases. The lead candidate is directed at acetyl-CoA carboxylase (ACC) for treating nonalcoholic steatohepatitis (NASH). An additional candidate, an IRAK4 inhibitor, is pursued to address Tyk2 and KRas pathways involved in immune signaling. Operations focus on advancing these programs through research and development.
Nimbus Therapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Nimbus Therapeutics offers TYK2 inhibitor, HPK1 inhibitor, and ACC inhibitor.
Nimbus Therapeutics has 21 investors. Key investors include Pfizer, Schrödinger, Citadel, RA Capital, and GSK.